Acute Myeloid Leukemia with Related Precursor Neoplasms

doi:10.1017/9781009105002.014

Chapter 14 - Acute Myeloid Leukemia with Related Precursor Neoplasms

from Section IV - Neoplastic Disorders of Bone Marrow

Published online by Cambridge University Press: 25 January 2024

Billie Carstens and

Edited by

Bradford Siegele and

Xiayuan Liang: Affiliation:
Children’s Hospital of Colorado
Bradford Siegele: Affiliation:
Children’s Hospital of Colorado
Jennifer Picarsic: Affiliation:
Cincinnati Childrens Hospital Medicine Center

Book contents

Get access

Summary

Acute myeloid leukemia (AML) is a heterogenous group of diseases representing a clonal expansion of immature, non-lymphoid, bone marrow–derived cells that involve the bone marrow and blood and may also be present in other tissues [1,2]. In the pediatric population, AML is less common than lymphoblastic leukemia, accounting for approximately 18% of childhood leukemia diagnoses [3]. Although the cause of AML in many cases is unknown [1], as molecular genetics has been evolving over the last couple of decades, new molecular technology has enhanced our knowledge of the underlying genetic defects and gene mutations associated with the development of AML. It has been demonstrated that AML occurs more commonly in children with pre-existing genetic disorders, such as Down syndrome (DS) or Fanconi anemia, and familial cases of AML are now recognized [1]. A subset arises from pre-existing myelodysplastic syndrome (MDS) or after therapy for another neoplasm.

Type: Chapter
Information: Pediatric Pathology of Hematopoietic and Histiocytic Disorders , pp. 155 - 188

DOI: https://doi.org/10.1017/9781009105002.014 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Arber, DA. Acute myeloid leukemia. In: Elaine, SJ, Arber, DA, Campo, E, et al., eds. Hematopathology, 2nd ed. Philadelphia, PA: Elsevier; 2017:817–45.Google Scholar

Arber, DA, Brunning, RD, Orazi, A, et al. Acute myeloid leukaemia, not otherwise specified. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:156–66.Google Scholar

Puumala, SE, Ross, JA, Aplenc, R, et al. Epidemiology of childhood acute myeloid leukemia. Pediatr Blood Cancer. 2013;60:728–33.CrossRef Google Scholar PubMed

Lorsbach, RB. Acute myeloid leukemia and related precursor neoplasms. In: Proytcheva, MA, ed. Diagnostic pediatric hematopathology. Cambridge, UK: Cambridge University Press; 2011:272–309.Google Scholar

Swerdlow, SH, Campo, E, Harris, NL, et al. Acute myeloid leukaemia and related precursor neoplasms. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon, France: IARC Press; 2008:109–47.Google Scholar

Swerdlow, SH, Campo, E, Harris, NL, et al. Acute myeloid leukaemia and related precursor neoplasms. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France; IARC Press; 2017:129–71.Google Scholar

Matynia, AP, Szankasi, P, Shen, W, et al. Molecular genetic biomarkers in myeloid malignancies. Arch Path Lab Med. 2015;139:594–601.Google Scholar

Arber, DA, Brunning, RD, Le Beau, MM, et al. Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:130–49.Google Scholar

Speck, NA, Gilliland, DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2002;2:502–13.Google Scholar

Raimondi, SC, Chang, MN, Ravindranath, Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POC8821. Blood. 1999;94:3707–16.Google Scholar

Rubnitz, JE, Raimondi, SC, Halbert, AR, et al. Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution’s experience. Leukemia. 2002;16;2072–7.Google Scholar

Tallman, MS, Hakimian, D, Shaw, JM, et al. Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol. 1993;11:690–7.Google Scholar

Johnson, RC, Savage, NM, Chiang, T, et al. Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol. 2013;140:525–35.Google Scholar

Forestier, E and Schmiegelow, K. The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations. J Pediatr Hematol Oncol. 2006;28:486–95.Google Scholar

Liu, P, Tarle, SA, Hajra, et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science. 1993;261: 1041–4.CrossRef Google Scholar

Gregory, J, Feusner, J. Acute promyelocytic leukemia in childhood. Curr Oncol Rep. 2009;11:439–45.CrossRef Google Scholar PubMed

Zhou, Yi, Jorgensen, JL, Wang, SA, et al. Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia. Am J Clin Pathol. 2012;138:744–50.Google Scholar

Stein, E, Tallman, MS. Acute promyelocytic leukemia in children and adolescents. Acta Haematol. 2014;132:307–12.Google Scholar

Rubnitz, JE, Raimondi, SC, Tong, X, et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol. 2002;20:2302–9.Google Scholar

Elzamly, S, Chavali, S, Tonk, V, et al. Acute myeloid leukemia with KMT2A-SEPT5 translocation: A case report and review of the literature. SAGE Open Med Case Rep. 2018;6:1–5.Google Scholar

Shih, LY, Liang, DC, Fu, JF, et al. Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement. Leukemia. 2006;20:218–23.Google Scholar

Sandahl, JD, Coenen, EA, Forestier, E, et al. t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. Haematologica. 2014;99:865–72.Google Scholar

Rogers, HJ, His, ED. Myeloid neoplasms with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Surg Pathol. 2013;6:677–92.Google Scholar

Maseti, R, Guidi, V, Ronchini, L, et al. The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children. Crit Rev Oncol Hematol. 2019;138:132–8.Google Scholar

Bernstein, J, Dastugue, N, Haas, OA, et al. Nineteen cases of the t(1;22)(p13;q13) acute megakaryoblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group. Leukemia. 2000;14:216–8.Google Scholar

Coenen, EA, Zwaan, CM, Reinhardt, D, et al. Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Münster AML-study group. Blood. 2013;122:2704–13.Google Scholar

Haferlach, T, Kohlmann, A, Klein, HU, et al. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia. 2009;23:934–43.Google Scholar

Dempsey, N, Khushmann, M, Hosein, P, et al. Acute myeloid leukemia with translocation (8;16)(p11;p13): a distinct syndrome – case report and literature review. Oncol Cancer Case Rep. 2017;3:2.Google Scholar

Braoudaki, M, Papathanassiou, C, Katsibardi, K, et al. The frequency of NPM1 mutations in childhood acute myeloid leukemia. J Hematol Oncol. 2010;3:41.Google Scholar

Falini, B, Martelli, MP, Bolli, N, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood. 2006;108:1999–2005.Google Scholar

Kansal, R. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA. Hum Pathol. 2019;90:80–96.CrossRef Google Scholar PubMed

Bacher, U, Schnittger, S, Macijewski, K, et al. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. Blood. 2012;119:4719–22.Google Scholar

Gaidzik, VI, Teleanu, V, Papaemmanuil, E. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. 2016;30:2160–8.Google Scholar

Arber, DA, Brunning, RD, Orazi, A, et al. Acute myeloid leukaemia with myelodysplasia-related changes. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:150–2.Google Scholar

Koenig, KL, Sahasrabudhe, KD, Sigmund, AM, et al. AML with myelodysplasia-related changes: development, challenges, and treatment advances. Genes. 2020;11:845–57.Google Scholar

Arber, DA, Erba, HP. Diagnosis and treatment of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC). Am J Clin Pathol. 2020;154:731–41.Google Scholar

Vardiman, JW, Arber, DA, Brunning, RD, et al. Therapy-related myeloid neoplasms. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:153–5.Google Scholar

Wang, SA. Myelodysplastic syndromes and therapy-related myeloid neoplasms. In: Proytcheva, MA, ed. Diagnostic pediatric hematopathology. Cambridge, UK: Cambridge University Press; 2011:253–71.Google Scholar

Harada, H, Harada, Y, Tanaka, H, et al. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood. 2003;101:673–80.Google Scholar

Pileri, SA, Orazi, A, Faomo, B. Myeloid sarcoma. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:167–8.Google Scholar

Samborska, M, Derwich, K, Skalska-Sadowska, J, et al. Myeloid sarcoma in children – diagnostic and therapeutic difficulties. Contemp Oncol (Pozn). 2016;20:444–8.Google Scholar

Bhatnagar, N, Nizery, L, Tunstall, O, et al. Transient abnormal myelopoiesis and AML in Down syndrome: an update. Curr Hematol Malig Rep. 2016;11:333–41.Google Scholar

Arber, DA, Baumann, I, Niemeyer, CM, et al. Myeloid proliferations associated with Down syndrome. In: Swerdlow, SH, Campo, E, Harris, NL et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:169–71.Google Scholar

Gamis, AS, Alonzo, TA, Gerbing, RB, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971. Blood. 2011;118:6752–9.Google Scholar

Choi, JK. Hematologic abnormalities in individuals with Down syndrome. In: Proytcheva, MA, ed. Diagnostic pediatric hematopathology. Cambridge, UK: Cambridge University Press; 2011:310–22.Google Scholar

Roy, A, Cowan, G, Mead, AJ, et al. Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. Proc Natl Acad Sci USA. 2012;109:17579–84.Google Scholar

Brink, DS. Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome. Adv Anat Pathol. 2006;13:256–62.Google Scholar

Book contents

Chapter 14 - Acute Myeloid Leukemia with Related Precursor Neoplasms

Summary

Access options

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive